Presentación del Formulario 8-K
MaxCyte announces filing of Form 8-K
ROCKVILLE, MD, 29 de enero de 2024 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announces that it has filed a Form 8-K with the SEC announcing the departure of Dr. Cenk Sumen as Chief Scientific Officer. Dr. Sumen will maintain a relationship with the Company as a member of MaxCyte's Scientific Advisory Board.
Una copia del Formulario 8-K está disponible para ver en el sitio web de la SEC en www.sec.gov y también se ha publicado en la página "Archivos de la SEC" del sitio web de la Compañía, https://investors.maxcyte.com/.
Acerca de MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT? platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx?, STx?, GTx? and VLx ?; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com y síguenos en X (anteriormente Twitter) y Etiqueta LinkedIn.
Contactos de MaxCyte:
Asesor de IR de EE. UU. Grupo Gilmartin David Deuchler | +1 415-937-5400
|
Consejero Designado y Sociedad Conjunta Broker panmure gordon Emma Earl/Freddy Crossley Corretaje corporativo Rupert Dearden
|
44 0 20 7886 2500 |
Asesor de RI del Reino Unido Consejo ICR Mary Jane Elliott chris galés
|
44 0 203 709 5700
|
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.